Evidence map›Paper›PMID 35990648›Full record

ArticleFrontiers in immunology2022

Recent malaria does not substantially impact COVID-19 antibody response or rates of symptomatic illness in communities with high malaria and COVID-19 transmission in Mali, West Africa.

John Woodford, Issaka Sagara, Halimatou Diawara, Mahamadoun Hamady Assadou, Abdoulaye Katile, Oumar Attaher, Djibrilla Issiaka, Gaoussou Santara, Ibrahim H Soumbounou, Seydou Traore and 14 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 2 institutions in 2 countries.

John WoodfordLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States.
Issaka SagaraMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Halimatou DiawaraMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Mahamadoun Hamady AssadouMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Abdoulaye KatileMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Oumar AttaherMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Djibrilla IssiakaMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Gaoussou SantaraMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Ibrahim H SoumbounouMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Seydou TraoreMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Moussa TraoreMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Oumar M DickoMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Sidi Mohamed NiambeleMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Almahamoudou MahamarMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Bourama KamateMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Bayaya HaidaraMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Kourane SissokoMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Seydou SankareMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Sadio Dite Koni DiarraMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Amatigue ZeguimeMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Justin Y A DoritchamouLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States.
Irfan ZaidiLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States.
Alassane DickoMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Patrick E DuffyLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States.
Université des Sciences, des Techniques et des Technologies de Bamako · MLNational Institute of Allergy and Infectious Diseases · US

Funding

COVID-19 Serosurveys and Vaccine Study Site PreparationsZIAAI001261 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DUFFY, PATRICK · 2020 to 2025
$2.4M
6 · The paper itself

Abstract

Malaria has been hypothesized as a factor that may have reduced the severity of the COVID-19 pandemic in sub-Saharan Africa. To evaluate the effect of recent malaria on COVID-19 we assessed a subgroup of individuals participating in a longitudinal cohort COVID-19 serosurvey that were also undergoing intensive malaria monitoring as part of antimalarial vaccine trials during the 2020 transmission season in Mali. These communities experienced a high incidence of primarily asymptomatic or mild COVID-19 during 2020 and 2021. In 1314 individuals, 711 were parasitemic during the 2020 malaria transmission season; 442 were symptomatic with clinical malaria and 269 had asymptomatic infection. Presence of parasitemia was not associated with new COVID-19 seroconversion (29.7% (211/711) vs. 30.0% (181/603), p=0.9038) or with rates of reported symptomatic seroconversion during the malaria transmission season. In the subsequent dry season, prior parasitemia was not associated with new COVID-19 seroconversion (30.2% (133/441) vs. 31.2% (108/346), p=0.7499), with symptomatic seroconversion, or with reversion from seropositive to seronegative (prior parasitemia: 36.2% (64/177) vs. no parasitemia: 30.1% (37/119), p=0.3842). After excluding participants with asymptomatic infection, clinical malaria was also not associated with COVID-19 serostatus or symptomatic seroconversion when compared to participants with no parasitemia during the monitoring period. In communities with intense seasonal malaria and a high incidence of asymptomatic or mild COVID-19, we did not demonstrate a relationship between recent malaria and subsequent response to COVID-19. Lifetime exposure, rather than recent infection, may be responsible for any effect of malaria on COVID-19 severity.

Indexed as

COVID-19MalariaAntibody FormationAsymptomatic InfectionsHumansMaliPandemicsParasitemiaCOVID-19falciparummalariaserologyseverityWest Africa

Identifiers

PMID35990648
PMCPMC9382593
OpenAlexW4289545203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.